Cardiology Headline News

Overreliance on high-sensitivity troponin as the sole assay to diagnose heart attacks has led to a rise in misdiagnosis, which is not benign and burdens the health system and patients with unnecessary and sometimes invasive testing.

A narrative review found no evidence that sodium restriction affects morbidity and mortality in patients with heart failure.

Antihypertensive medications may lower patients’ risk for developing acne within 5 years of therapy initiation, according to a study.

The association between daily alcohol consumption and risk for hypertension is a linear relationship and the strength of the association varied between men and women, researchers reported.

In this episode, we dive into the story of aspirin and the development of ibuprofen, ending with the experiments that showed the mechanism of how aspirin actually works.

ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.

Treatment with the novel antibody CM313 boosted platelet levels and demonstrated long-term durability among adults with immune thrombocytopenia, results from a phase 2 study showed.

AliveCor announced the FDA clearance and launch of its AI system designed to detect 35 cardiac conditions using a reduced leadset, in addition to its single-cable, AI-powered handheld ECG System.

In patients with obesity-driven heart failure with preserved ejection fraction, semaglutide 2.4 mg was associated with more improvement in NYHA functional class compared with placebo, according to new data from the STEP-HFpEF trials.

Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.